{
    "id": "35d31421-2856-1e64-e063-6294a90a9ccd",
    "indications": "venlafaxine hydrochloride extended-release capsules indicated adults treatment : major depressive disorder ( mdd ) [ ( 14.1 ) ] generalized anxiety disorder ( gad ) [ ( 14.2 ) ] social anxiety disorder ( sad ) [ ( 14.3 ) ] panic disorder ( pd ) [ ( 14.4 ) ]",
    "contraindications": "indication starting dose target dose maximum dose mdd ( 2.2 ) 37.5 75 mg/day 75 mg/day 225 mg/day gad ( 2.3 ) 37.5 75 mg/day 75 mg/day 225 mg/day sad ( 2.4 ) 75 mg/day 75 mg/day 75 mg/day pd ( 2.5 ) 37.5 mg/day 75 mg/day 225 mg/day take daily food . capsules taken whole ; divide , crush , chew , dissolve ( 2.1 ) . discontinuing treatment , reduce dose gradually ( 2.10 , 5.7 ) . renal impairment : reduce total daily dose 25 % 50 % patients renal impairment . reduce total daily dose 50 % patients undergoing dialysis severe renal impairment ( 2.9 ) . hepatic impairment : reduce daily dose 50 % patients mild moderate hepatic impairment . patients severe hepatic impairment hepatic cirrhosis , may necessary reduce dose 50 % ( 2.8 ) .",
    "warningsAndPrecautions": "venlafaxine hydrochlorid e extended-release capsules , usp 37.5 mgare white white spherical oval pellets filled empty hard gelatin capsule shell ( size ‘ 3 ’ ) opaque grey color cap opaque peach color body imprinted “ e ” cap “ 73 ” body edible black ink . ndc 60760-836-30 botles 30 store at20° 25°c ( 68° 77°f ) . [ usp controlled room temperature . ]",
    "adverseReactions": "venlafaxine hydrochloride extended-release capsules contraindicated patients : known hypersensitivity venlafaxine hydrochloride , desvenlafaxine succinate excipients formulation [ ( 6.2 ) ] . taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) risk serotonin syndrome [ ( 2.11 ) , ( 5.2 ) , ( 7.1 ) ] .",
    "ingredients": [
        {
            "name": "ETHYLCELLULOSE (20 MPA.S)",
            "code": "BJG0S321QY"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "VENLAFAXINE HYDROCHLORIDE",
            "code": "7D7RX5A8MO"
        }
    ],
    "organization": "ST. MARY'S MEDICAL PARK PHARMACY",
    "name": "Venlafaxine Hydrochloride",
    "effectiveTime": "20250523",
    "indications_original": "Venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of:\n                  \n                  \n                     Major Depressive Disorder (MDD)\n  \n   [see\n   \n    Clinical Studies (14.1)]\n  \n   \n                     \n                     Generalized Anxiety Disorder (GAD)\n  \n   [see\n   \n    Clinical Studies (14.2)]\n  \n   \n                     \n                     Social Anxiety Disorder (SAD)\n  \n   [see\n   \n    Clinical Studies (14.3)]\n  \n   \n                     \n                      Panic Disorder (PD)\n  \n   [see\n   \n    Clinical Studies (14.4)]",
    "contraindications_original": "Indication Starting Dose Target Dose Maximum Dose MDD ( 2.2 ) 37.5 to 75 mg/day 75 mg/day 225 mg/day GAD ( 2.3 ) 37.5 to 75 mg/day 75 mg/day 225 mg/day SAD ( 2.4 ) 75 mg/day 75 mg/day 75 mg/day PD ( 2.5 ) 37.5 mg/day 75 mg/day 225 mg/day Take once daily with food. Capsules should be taken whole; do not divide, crush, chew, or dissolve ( 2.1 ). When discontinuing treatment, reduce the dose gradually ( 2.10 , 5.7 ). Renal impairment: reduce the total daily dose by 25% to 50% in patients with renal impairment. Reduce the total daily dose by 50% or more in patients undergoing dialysis or with severe renal impairment ( 2.9 ). Hepatic impairment: reduce the daily dose by 50% in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment or hepatic cirrhosis, it may be necessary to reduce the dose by more than 50% ( 2.8 ).",
    "warningsAndPrecautions_original": "Venlafaxine Hydrochlorid\n                     e Extended-Release Capsules, USP\n                     37.5 mgare white to off white spherical to oval pellets filled in empty hard gelatin capsule shell (size ‘3’) of opaque grey color cap and opaque peach color body imprinted with “E” on cap and “73” on the body with edible black ink.\n \n                  \n                  \n                  NDC 60760-836-30 BOTLES OF 30\n                  \n                  \n                     \n                     Store at20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]",
    "adverseReactions_original": "Venlafaxine hydrochloride extended-release capsules are contraindicated in patients:\n                  \n                  \n                     with known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation\n  \n   [see\n   \n    Adverse Reactions (6.2)]\n  \n   .\n \n  \n                  \n                  \n                  \n                      taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of the risk of serotonin syndrome\n  \n   [see\n   \n    Dosage and Administration (2.11),\n   \n    Warnings and Precautions (5.2), and\n   \n    Drug Interactions (7.1)]\n  \n   ."
}